Last reviewed · How we verify

NCT06018935

A Cohort Establishment Study of Total Management of Ovarian Cancer

Recruiting now Last updated 20 June 2024
What this trial tests

trial testing No intervention in Tumor of Female Reproductive System in 500 participants. Currently enrolling.

Timeline
17 June 2024
Primary endpoint
1 September 2025
1 September 2025

Quick facts

Lead sponsorSichuan Cancer Hospital and Research Institute
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment500
Start date17 June 2024
Primary completion1 September 2025
Estimated completion1 September 2025
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Sichuan Cancer Hospital and Research Institute

Who can join

Eligibility, female only, with Tumor of Female Reproductive System or Ovarian Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A cohort establishment study of total management of ovarian cancer (including fallopian tube cancer and primary peritoneal cancer).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of No intervention

Trials testing the same drug.

Other Sichuan Cancer Hospital and Research Institute trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06018935.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing